START (STem cells for ARDS Treatment) is an exciting new clinical trial for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS). Preclinical studies have shown Mesenchymal Stem Cells to be effective at reducing the severity of organ injury as well as enhancing recovery. This is the first clinical trial to use Mesenchymal Stem Cells as a treatment for patients with severe ARDS.


This study is now open for recruitment, and patients can be referred to University of California- San Francisco (UCSF), Stanford, Massachusetts General, University of Pittsburgh, or The Ohio State University Medical Centers to be considered for this trial. Phase 1 of the study has been completed and Phase 2 is currently in progress. See the “Contact” page for details about who to contact at each specific site.